Actively Recruiting
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Led by University of Vermont Medical Center · Updated on 2026-02-23
16
Participants Needed
1
Research Sites
229 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.
CONDITIONS
Official Title
Pyridostigmine for the Treatment of Constipation in Parkinson Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Ability to provide signed informed consent
- Willingness and ability to follow all study procedures
- Ability to take oral medications
- Females of reproductive potential who are sexually active must use two highly effective contraception methods during and 28 days after treatment, or one method plus partner use of barrier contraception
- Males of reproductive potential who are sexually active must use barrier contraception during and 28 days after treatment, and partner must use effective contraception
- Meet UK Parkinson's Disease Society Brain Bank Criteria for parkinsonism diagnosis
- Meet ROME IV Criteria for Functional Constipation, including three or fewer defecations per week and related symptoms for at least three months, with onset at least six months before diagnosis
You will not qualify if you...
- Diagnosis of atypical, drug-induced, or vascular parkinsonism
- Known allergy to pyridostigmine bromide or study drug components
- Current or recent (within 90 days) use of pyridostigmine
- History of bowel surgery
- History of bladder or bowel obstruction
- Severe asthma or chronic obstructive pulmonary disease
- Exclusion criteria from UK Parkinson's Disease Society Brain Bank Criteria at investigator discretion, including repeated strokes, head injury, encephalitis, neuroleptic treatment at symptom onset, and others
- Significant abnormalities in laboratory tests within three months before screening
- Significant abnormalities on screening electrocardiogram within three months before screening
- Positive pregnancy test for females of childbearing age
- Antibiotic use within two weeks before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Vermont Medical Center
Burlington, Vermont, United States, 05401
Actively Recruiting
Research Team
K
Kaysi Herrera Pujols
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here